Search
PMI-001
go.drugbank.com/drugs/DB05730ExperimentalPMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.
LU-31130
go.drugbank.com/drugs/DB05828ExperimentalLU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.
anti-alpha5Beta1-integrin antibody
go.drugbank.com/drugs/DB05870ExperimentalThe integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial
Dexchlorpheniramine
go.drugbank.com/drugs/DB13679InvestigationalIt disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.
Xanthine
go.drugbank.com/drugs/DB02134InvestigationalIt is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine.
1D-myo-inositol 1,4,5-trisphosphate
go.drugbank.com/drugs/DB03401ExperimentalIntracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane.
Arsthinol
go.drugbank.com/drugs/DB08928ExperimentalArsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol.
GRAd-COV2
go.drugbank.com/drugs/DB16428InvestigationalGRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423].
BB-301
go.drugbank.com/drugs/DB17011Investigational[A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062]
Cilobradine
go.drugbank.com/drugs/DB20039InvestigationalCilobradine is under investigation in clinical trial NCT02264041 (Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine).